180 related articles for article (PubMed ID: 22801569)
1. Rare presentation of occult medullary carcinoma of the thyroid as a mediastinal mass.
Daraki V; Koukouraki S; Velegrakis G; Mamalaki E; Haniotis VT; Kalikakis G; Stathaki MI; Karkavitsas N; Papavasiliou SS
Hormones (Athens); 2012; 11(2):210-4. PubMed ID: 22801569
[TBL] [Abstract][Full Text] [Related]
2. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
3. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
5. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Becker H; Becker W
Eur J Nucl Med; 1997 Feb; 24(2):184-91. PubMed ID: 9021116
[TBL] [Abstract][Full Text] [Related]
6. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
7. [Medullar carcinoma of the thyroid gland: surgical treatment of mediastinal metastases].
Plaza G; Argüelles M; Donnay S; Ferrando J; Criado E; de los Santos G
An Otorrinolaringol Ibero Am; 2004; 31(4):355-64. PubMed ID: 15382487
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
Cano JM; Galán R; López R
Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
[TBL] [Abstract][Full Text] [Related]
9. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
Szakáll S; Esik O; Bajzik G; Repa I; Dabasi G; Sinkovics I; Agoston P; Trón L
J Nucl Med; 2002 Jan; 43(1):66-71. PubMed ID: 11801705
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid cancer with undetectable serum calcitonin.
Brutsaert EF; Gersten AJ; Tassler AB; Surks MI
J Clin Endocrinol Metab; 2015 Feb; 100(2):337-41. PubMed ID: 25490273
[TBL] [Abstract][Full Text] [Related]
12. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
Papapetrou PD; Polymeris A
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
[TBL] [Abstract][Full Text] [Related]
13. Mixed medullary-papillary carcinoma of the thyroid with lymph node metastases: report of a case.
Shiroko T; Yokoo N; Okamoto K; Kitakado Y; Azuma H; Fukui T; Tanaka C
Surg Today; 2001; 31(4):317-21. PubMed ID: 11321340
[TBL] [Abstract][Full Text] [Related]
14. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological analysis of superior mediastinal lymph node metastases in medullary thyroid carcinoma].
He YY; Chen YT; Wang J; Chen MQ; Zhu YM; Ni S; Liu SY
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):82-87. PubMed ID: 36709124
[No Abstract] [Full Text] [Related]
16. Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery.
Schott M; Willenberg HS; Sagert C; Nguyen TB; Schinner S; Cohnen M; Cupisti K; Eisenberger CF; Knoefel WT; Scherbaum WA
Clin Endocrinol (Oxf); 2007 Mar; 66(3):405-9. PubMed ID: 17302876
[TBL] [Abstract][Full Text] [Related]
17. Medullary carcinoma of the thyroid with axillary metastasis: a case report.
Ozdemir M; Makay O; Simsir I; Ertan Y; Icoz G; Saygili F; Akyildiz M
Int Surg; 2015 Mar; 100(3):390-3. PubMed ID: 25785315
[TBL] [Abstract][Full Text] [Related]
18. Surgery for lymph node metastases of medullary thyroid carcinoma: A review.
Jin LX; Moley JF
Cancer; 2016 Feb; 122(3):358-66. PubMed ID: 26539937
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
